Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy IGM Biosciences stock

Own IGM Biosciences stock in just a few minutes.

IGM Biosciences, Inc is a biotechnology business based in the US. IGM Biosciences shares (IGMS) are listed on the NASDAQ and all prices are listed in US Dollars. IGM Biosciences employs 107 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in IGM Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IGMS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

IGM Biosciences share price

Use our graph to track the performance of IGMS stocks over time.

IGM Biosciences shares at a glance

Information last updated 2021-04-29.
52-week range$41.41 - $127.11
50-day moving average $75.43
200-day moving average $79.05
Wall St. target price$101.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-71.75

Buy IGM Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy IGM Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

IGM Biosciences financials

Gross profit TTM $-39,161,000
Return on assets TTM -15.54%
Return on equity TTM -26.16%
Profit margin 0%
Book value $8.35
Market capitalisation $2.2 billion

TTM: trailing 12 months

Shorting IGM Biosciences shares

There are currently 3.0 million IGM Biosciences shares held short by investors – that's known as IGM Biosciences's "short interest". This figure is 15.5% down from 3.6 million last month.

There are a few different ways that this level of interest in shorting IGM Biosciences shares can be evaluated.

IGM Biosciences's "short interest ratio" (SIR)

IGM Biosciences's "short interest ratio" (SIR) is the quantity of IGM Biosciences shares currently shorted divided by the average quantity of IGM Biosciences shares traded daily (recently around 244214.59854015). IGM Biosciences's SIR currently stands at 12.33. In other words for every 100,000 IGM Biosciences shares traded daily on the market, roughly 12330 shares are currently held short.

However IGM Biosciences's short interest can also be evaluated against the total number of IGM Biosciences shares, or, against the total number of tradable IGM Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IGM Biosciences's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 IGM Biosciences shares in existence, roughly 90 shares are currently held short) or 0.3559% of the tradable shares (for every 100,000 tradable IGM Biosciences shares, roughly 356 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against IGM Biosciences.

Find out more about how you can short IGM Biosciences stock.

IGM Biosciences share dividends

We're not expecting IGM Biosciences to pay a dividend over the next 12 months.

IGM Biosciences overview

IGM Biosciences, Inc. , a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site